Hani Kushlaf

Associate Professor of Neurology & Pathology

University of Cincinnati

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Hani Kushlaf is an Associate Professor of Neurology & Pathology at the University of Cincinnati, USA. His research focuses on neuromuscular disorders, including inclusion body myositis, Pompe disease, and amyotrophic lateral sclerosis. Recent publications explore advancements in disease-modifying therapeutics and biomarker development, contributing to improved diagnostic and therapeutic strategies in his field.

Articles (21)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Wolfgang Löscher

Medical University of Innsbruck

AUSTRIA

View details

Kendrea Garand

Associate Professor

University of Pittsburgh

UNITED STATES

View details

Sheetal Shroff

Houston Methodist Hospital

UNITED STATES

View details

Bhaskar Roy

Assistant Professor

Yale University School of Medicine

UNITED STATES

View details

Meredith K James

UNITED KINGDOM

View details

Agnes Sebok

Assistant Professor

University of Pecs

HUNGARY

View details

giancarlo parenti

Full Professor

Università degli Studi di Napoli Federico II

ITALY

View details

Roberto D. Fanganiello

Professor and Researcher in Regenerative Biology, Bioengineering and Biomaterials

Laval University

CANADA

View details

Anny-Claude Joseph

Assistant Professor

Wellesley College

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hani Kushlaf

Research Interests

Explore related searches

Contact this professor

About

Articles (21)

Lymphocyte Activation Gene 3 in Inclusion Body Myositis: A Novel Therapeutic Biomarker?

Switching Enzyme Replacement Therapy for Late‐Onset Pompe Disease From Alglucosidase Alfa to Cipaglucosidase Alfa Plus Miglustat: Post Hoc Effect Size Analysis of PROPEL

Muscle Biopsy Findings in Valosin-Containing Protein Multisystem Proteinopathy.

Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial.

Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders

Global variations in diagnostic methods and epidemiological estimates in Pompe disease: findings from a scoping review.

RNA Sequencing Confirms the Pathogenicity of a Novel FHL1 Deletion in a Kinship With Emery-Dreifuss Muscular Dystrophy.

Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study

Lack of Relationship Between Myasthenia Gravis and COVID-19 Severity

Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial.

Design and Statistical Innovations in a Platform Trial for ALS

Provisional practice recommendation for the management of myopathy in VCP-associated multisystem proteinopathy.

Current status of clinical outcome measures in inclusion body myositis: a systematised review.

The applicability of the myasthenia gravis patient registry data to disease burden and medication changes in clinical practice

Patient preference for virtual versus in‐person visits in neuromuscular clinical practice

Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis

Development of a standard of care for patients with valosin-containing protein associated multisystem proteinopathy.

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial.

Steps in Inclusion Body Myositis

How does rituximab fit in the treatment algorithm of myasthenia gravis?

Collaborators (9)

Wolfgang Löscher

Kendrea Garand

Sheetal Shroff

Bhaskar Roy

Meredith K James

Agnes Sebok

giancarlo parenti

Roberto D. Fanganiello

Anny-Claude Joseph

Make your next move.